Ovarian PRP: What It Is, Who It Helps, and What the Research Actually Shows
- Hace 2 días
- 11 minutos de lectura
Updated: 1 day ago
Quick answer: Ovarian PRP is a procedure that injects a concentrated dose of your own platelets, and the growth factors they carry, directly into your ovaries to support the follicles already there. It is used for women with low AMH, diminished ovarian reserve, or premature ovarian insufficiency who want to pursue pregnancy with their own eggs.
Published cohorts report pregnancies and live births in women who had previously been told IVF would not work for them, and Rejuvenating Fertility Center has published the first documented live births in women over 45 using an adipose-enriched version of the technique. Whether ovarian PRP is right for you depends on your reserve, your history, and which version of the procedure you receive.
What Is Ovarian PRP, and Why Does It Matter for Fertility?
You have probably already had the appointment where someone looked at your AMH, said the number was low, and moved straight to donor eggs. You have probably read that ovarian reserve only goes one direction. And you are probably here because you want to know whether there is anything that acts on the ovary itself instead of just stimulating it harder.
Ovarian PRP, also called platelet rich plasma ovarian rejuvenation, is that category of treatment. Platelets are not just clotting cells. They carry a dense payload of growth factors, including VEGF, IGF-1, TGF-beta, and PDGF, that the body uses to rebuild tissue and grow new blood vessels. Ovarian PRP concentrates those platelets from your own blood and places them inside the ovary, where the goal is to improve the local environment around follicles that are already present but not responding.
This matters because ovarian reserve is not only about how many follicles remain. It is also about whether those follicles are getting the blood supply and signaling they need to mature. That second part is potentially modifiable, and that is the whole premise of ovarian rejuvenation at Rejuvenating Fertility Center.
Ovarian PRP is typically considered for women who:
Have low AMH or a low antral follicle count, including AMH close to zero
Have been diagnosed with diminished ovarian reserve or poor ovarian response
Have premature ovarian insufficiency or early menopause
Have produced few or no eggs in previous IVF cycles
Are over 40 and want to use their own eggs
Were declined by another clinic based on age, AMH, or BMI
RFC has no age cutoff and no weight cutoff. If a number on a lab report is the reason you were turned away somewhere else, it is not the reason you will be turned away here.
Why Patients Ask About Ovarian PRP
They want to use their own eggs
This is the single most common reason. Donor eggs are an excellent path with outstanding outcomes, and RFC's own donor egg program reports 95% egg thaw survival and an 82% clinical pregnancy rate. But wanting a genetic connection to your child is a legitimate goal, and ovarian PRP exists to give that goal a real attempt before you decide anything else.
Their IVF cycles keep getting cancelled
If you have had cycles cancelled for low response, or retrievals that produced one egg or none, the problem is usually recruitment, not the protocol dose. Higher stimulation does not create follicles that are not responding. Ovarian PRP is aimed at that upstream problem, and it is often paired with gentle or mini IVF rather than maximal stimulation.
They have been told their AMH is "too low to treat"
AMH predicts how many eggs a stimulation cycle will yield. It does not predict whether any given egg can become a healthy baby. Women with very low AMH conceive, and the published ovarian PRP cohorts include women whose AMH was near undetectable at baseline. If you want the fuller picture on this, our post on egg quality after 40 covers what the research does and does not support.
They want something the ovary responds to, not just more medication
Ovarian PRP sits alongside other regenerative options at RFC, including bone marrow stem cell-enriched PRP and Super Ovarian Rejuvenation. Which one fits depends on your reserve and your history, and that is a conversation, not a menu.
How Ovarian PRP Works, Step by Step
The procedure itself is short. Most of the timeline is what happens afterward.
Baseline testing. AMH, FSH, estradiol, and an antral follicle count on ultrasound establish where you are starting. Thyroid and vitamin D are usually checked at the same time.
Blood draw. A standard peripheral blood draw, typically 30 to 60 mL.
Concentration. The blood is centrifuged to separate and concentrate the platelet fraction. Platelet concentration in the final product is several times higher than in whole blood.
Activation. The PRP is activated, commonly with calcium chloride, so the growth factors release once injected.
Injection. Under sedation, the PRP is injected into both ovaries using a transvaginal ultrasound-guided needle, the same route used for egg retrieval. The procedure takes roughly 15 to 20 minutes.
Recovery. Most patients go home the same day and return to normal activity within 24 hours.
Follow-up. AMH, FSH, and antral follicle count are rechecked at intervals, usually around 1 to 3 months. Any planned IVF cycle is generally timed for that window.
Where the PRP is placed inside the ovary matters. Antral follicles sit near the ovarian surface, so subcapsular placement rather than deep medullary injection is a technical detail that changes what the tissue is actually exposed to. RFC's medical director has argued this point directly in the peer-reviewed literature (Merhi, Human Reproduction, 2024), and it is one reason results vary so much between centers.
What the Research Shows: Ovarian PRP Outcomes
The honest summary is that the observational evidence is encouraging and the randomized evidence is mixed. Both things are true, and you deserve to see both.
The largest single cohort followed 510 women with poor ovarian response, mean age 40.3, treated with intraovarian PRP. Antral follicle count and AMH rose, FSH fell, and the group achieved a 20.5% pregnancy rate and a 12.9% sustained implantation or live birth rate (Cakiroglu et al., Aging, 2022). In an earlier cohort of 311 women with primary ovarian insufficiency, 64.8% developed antral follicles and went on to attempt IVF, and 7.4% conceived spontaneously (Cakiroglu et al., Aging, 2020).
A 2025 meta-analysis pooling 23 studies and 1,853 women found that in women with premature ovarian insufficiency, PRP was associated with improvements in antral follicle count, AMH, FSH, and LH, with a pooled pregnancy ratio of 0.21 and live birth ratio of 0.18 in poor ovarian reserve (Sadeghpour et al., European Journal of Medical Research, 2025).
Safety has been consistent across the literature. A single-center series of 469 women reported no significant procedural complications (Fraidakis et al., Cureus, 2023). Because ovarian PRP uses your own blood, there is no rejection risk and no donor exposure.
Ovarian PRP outcomes at a glance
Population | Estudio | N | Pregnancy rate | Live birth / sustained implantation |
Poor ovarian response, mean age 40.3 | Cakiroglu et al., Aging, 2022 | 510 | 20.5% | 12.9% |
Primary ovarian insufficiency, age 24 to 40 | Cakiroglu et al., Aging, 2020 | 311 | 7.4% spontaneous | Not reported as pooled rate |
Poor ovarian reserve, pooled | Sadeghpour et al., Eur J Med Res, 2025 | 23 studies, 1,853 women | 21% | 18% |
Premature ovarian insufficiency, pooled | Sadeghpour et al., Eur J Med Res, 2025 | 23 studies, 1,853 women | 13.8% | 10% |
Younger poor responders, randomized | Herlihy et al., Human Reproduction, 2024 | 83 | No significant difference vs. control | No significant difference vs. control |
Why Two Randomized Trials Came Back Negative, and Who Ovarian PRP Still Helps
This is the question almost no article answers directly, so here it is.
In 2024, two randomized controlled trials in Human Reproduction found no significant benefit from intraovarian PRP. The PROVA trial reported a mean of 3.1 mature oocytes in the PRP group versus 2.8 in controls, a difference that was not statistically significant (Herlihy et al., Human Reproduction, 2024). A double-blind randomized trial reached a similar conclusion on euploid blastocyst rates (Barrenetxea et al., Human Reproduction, 2024).
Those are real findings and they should change how ovarian PRP is discussed. They should not be read as "PRP does nothing." Here is why.
The trials tested one specific version of the procedure. PRP is not a standardized drug. Platelet concentration, activation method, injected volume, injection depth, and timing relative to stimulation all differ between centers, and none of them are fixed by a regulatory definition. Two centers can both say "ovarian PRP" and be delivering measurably different products. Dr. Merhi made exactly this argument in a published exchange with the trial authors, focusing on subcapsular placement, preparation method, and injection timing (Merhi, Human Reproduction, 2024).
The trials enrolled specific populations. PROVA studied younger women with poor ovarian response, a group whose eggs are already relatively competent. The observational cohorts reporting the strongest signals were weighted toward women in their 40s with far lower reserve. A treatment can be neutral in one group and meaningful in another.
The endpoints were short-term. Oocyte yield in the next cycle is a fast, measurable endpoint. It is not the same question as whether a woman with AMH of 0.1 who has been declined elsewhere can produce a transferable embryo at all.
What follows from this is not that the evidence is settled either way. It is that the version of ovarian PRP you receive, and the team performing it, are not interchangeable variables. RFC treats them as the treatment.
Standard Ovarian PRP vs. Adipose-PRP: How to Decide
This is where RFC differs from most clinics offering ovarian rejuvenation, and it is the difference most patients have never had explained to them.
Standard ovarian PRP delivers platelets and their growth factors only. It is the version studied in nearly all of the literature above. It is less invasive, faster, and less expensive.
Adipose ovarian PRP combines PRP with mechanically processed adipose nanofat, which is rich in adipose-derived stem cells (ADSCs). The stem cells contribute their own paracrine and angiogenic signaling, and the published mechanistic work indicates the combination acts more strongly than either component alone (Merhi, Future Science OA, 2025). The adipose is processed mechanically rather than enzymatically, which keeps the procedure within FDA minimal manipulation guidelines.
RFC published the first documented live births in women over 45 using this combined approach. Two patients, ages 45 and 46, both with extremely diminished ovarian reserve and multiple failed IVF cycles, one of whom had been turned away by other clinics for age, went on to deliver healthy infants (Merhi et al., American Journal of Stem Cells, 2025). That work was covered twice by Forbes.
Standard ovarian PRP | Adipose-PRP | Bone marrow stem cell-enriched PRP | |
What is injected | Concentrated autologous platelets | Platelets plus adipose-derived stem cells from nanofat | Platelets plus mobilized autologous bone marrow stem cells |
Source tissue | Blood only | Blood plus a small fat harvest | Blood plus bone marrow |
Typically suited for | Low AMH, poor response, reserve still measurable | Very low or near-zero AMH, age 40+, prior failed cycles | Very low reserve or ovarian failure |
Procedure length | About 15 to 20 minutes | Longer, includes fat harvest | Longer, includes marrow collection |
Published RFC outcome | Improved blastocyst euploidy rates (Merhi et al., Clin Exp Reprod Med, 2022) | First reported live births over age 45 | Reported follicular reactivation |
The right choice depends on your AMH, your antral follicle count, your age, how many cycles you have already done, and whether you have conditions like endometriosis or an immune factor that need addressing in parallel. If you are under 40 with an AMH above 1.0 and a straightforward history, our sister clinic Aurea Fertility is usually the better starting point.
Cost, Timeline, and What to Expect
PRP cost varies by region, by whether stem cells are included, and by how many treatments are planned. Nationally, standard ovarian PRP is commonly quoted in the range of roughly $1,500 to $5,000 per treatment, with stem cell-enriched versions priced higher because of the additional harvest and processing. Ovarian PRP is generally not covered by insurance, and it is usually billed separately from any IVF cycle. Current RFC figures are on our pricing page.
What to have tested first. Ask for AMH, day 2 or 3 FSH and estradiol, an antral follicle count by transvaginal ultrasound, TSH, and vitamin D. If you have had prior IVF, bring the stimulation protocol, the doses used, the number of eggs retrieved, and the fertilization report. Those documents change the recommendation more than the AMH number alone does.
What to ask your reproductive endocrinologist. Which version of ovarian PRP do you perform, standard or stem cell-enriched? Where in the ovary do you inject? How is the PRP prepared and activated? When would you time an IVF cycle afterward? What would you consider a response worth acting on?
The first one to three months. Expect a recheck of AMH, FSH, and antral follicle count. Some women see measurable change by 4 to 6 weeks, others closer to 3 months. Response is not uniform, and a modest lab change can still be enough to make a retrieval possible that was not possible before. Any planned natural, mini, or conventional IVF cycle is usually scheduled inside that window, and egg freezing can be combined with it.
If you live outside New York or Connecticut, our outside monitoring program lets you do bloodwork and ultrasounds locally and travel in only for the procedure and retrieval. Geography does not need to be the reason you skip this.
Preguntas frecuentes
Does ovarian PRP actually work?
It depends on who is being treated and which version is used. Observational cohorts in women with poor ovarian response report pregnancy rates around 20% and live birth around 13% (Cakiroglu et al., Aging, 2022), while two 2024 randomized trials in different populations found no significant benefit. The technique is not standardized between centers, which is a large part of why results differ. That is a reason to ask detailed questions about protocol, not a reason to rule it out.
Is there an ovarian rejuvenation age limit?
Not at RFC. There is no age cutoff and no weight cutoff. The published RFC case series describes live births in women aged 45 and 46 using their own eggs after adipose-PRP (Merhi et al., American Journal of Stem Cells, 2025). Age changes the plan and the expected timeline. It does not close the conversation.
Can ovarian PRP work if my AMH is close to zero?
Very low AMH is one of the main reasons patients are referred for it. AMH reflects the number of follicles producing hormone, and PRP is aimed at the follicles that are present but quiet. Women with near-undetectable AMH are represented in the published cohorts, and this is exactly the profile RFC's adipose-PRP protocol was developed for.
Is ovarian PRP painful, and how long is recovery?
The injection is done under sedation, so you should not feel it. Afterward, most women describe mild cramping and pressure similar to the day after an egg retrieval, resolving within 24 to 48 hours. Most people return to normal activity the next day.
Is ovarian PRP safe?
PRP is autologous, meaning it comes from your own blood, so there is no rejection or donor transmission risk. A single-center series of 469 women reported no significant procedural complications (Fraidakis et al., Cureus, 2023). Long-term data on offspring outcomes is still accumulating, which is a reasonable thing to discuss at consultation.
How long do the effects of ovarian PRP last?
Reported effects on ovarian reserve markers are generally described over a window of several months rather than permanently, which is why IVF or egg retrieval is usually timed within one to three months of the procedure. Some patients repeat treatment. The plan should be built around your retrieval timing, not around the injection date alone.
En resumen
Ovarian PRP is not a guarantee, and it is not a dead end either. It is a real regenerative option with published pregnancies and live births behind it, including in women over 45 using their own eggs. What separates a meaningful result from a disappointing one is largely which version you receive, where in the ovary it is placed, and how the cycle around it is planned.
If you have been handed a number and told it decides everything, you have not yet had the full conversation.
Rejuvenating Fertility Center specializes in exactly the cases other clinics decline, with no age cutoff and no weight cutoff. If you want to know whether ovarian PRP or adipose-PRP fits your reserve and your history, reach out to schedule a consultation and bring your labs and prior cycle records. You can also read more about the full range of ovarian rejuvenation therapies or explore reproductive longevity testing at R&S Longevity.